Allarity Therapeutics says newly awarded patents bolster exclusivity strategy for stenoparib-DRP test
ALLR•Allarity Therapeutics said recently awarded patents tied to its Drug Response Predictor strategy for stenoparib aim to strengthen commercial exclusivity. The patents support use of the stenoparib-DRP test as a companion diagnostic and are a step toward a DRP-guided pivotal trial and eventual FDA filing, the company said.
1. Patent strategy
Allarity Therapeutics said recently awarded patents tied to its Drug Response Predictor strategy for stenoparib aim to strengthen commercial exclusivity. The company said the patents support use of its stenoparib-DRP test as a companion diagnostic while allowing it to retain control of the clinical test. Management framed the patent progress as a step toward a DRP-guided pivotal trial for stenoparib and an eventual FDA filing.
